Summary: CND Life Sciences’ Syn-Sleep Study found phosphorylated alpha-synuclein in 75% of patients with idiopathic REM sleep behavior disorder at baseline, supporting the use of skin biopsy as a potential biomarker for early detection and future progression of synucleinopathies like Parkinson’s disease. Key Takeaways:A new research abstract presented at SLEEP 2025 detected phosphorylated alpha-synuclein in 75% of patients with idiopathic REM sleep behavior disorder at baseline. So far, results have shown phosphorylated alpha-synuclein detection in 75% of patients with idiopathic REM sleep behavior disorder (iRBD) at baseline. Idiopathic REM sleep behavior disorder is a well-established early indicator of future neurodegenerative conditions involving phosphorylated alpha-synuclein (P-SYN). One scientific paper showed that 73.5% of patients diagnosed with idiopathic REM sleep behavior disorder (n=1,280) converted to Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy within 12 years.